Biogen profit beats on surprisingly strong Spinraza sales

(Reuters) - Biogen Inc's quarterly profit blew past analysts' estimates, helped by higher-than-expected sales of its recently launched spinal muscular atrophy drug, Spinraza.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news